Proactive Investors
20 Oct 2026, 02:01 UTC · 1h ago
Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review
Impact · against what's priced in
Recce Pharmaceuticals reaches a critical binary milestone as an independent committee reviews unblinded Phase 3 data for diabetic foot infections. While blinded data is encouraging, the upcoming mid-November DMC recommendation serves as the primary catalyst for valuation.
- RCE+0.60
No priced-in read yet
- In context
The submission of data for 75 patients to an independent DMC for unblinded review is a major step toward regulatory submission, supported by encouraging blinded clinical outcomes and safety profiles.
Read from the article alone
Top 1 mover · tap to explore
